The FDA panel that convened for an intense, two-day review of drug-eluting stents last week heard key testimony from ...
A strong grassroots effort among physicians played a key role in staving off a Medicare physician payment cut that would ...
FUJIFLM Medical Systems USA, Inc. (“Fuji”) and Problem Solving Concepts, Inc. (“ProSolv”) have announced a co-marketing ...
SPONSORED CONTENT — Studycast is a comprehensive imaging workflow system that allows healthcare professionals to work ...
Agfa HealthCare has signed a contract with the National Heart Centre (NHC) of Singapore, the national referral centre ...
The FDA panel that is re-evaluating the safety of drug-eluting stents convenes Dec. 7 and 8 at the Hilton Washington DC ...
Taking anti-platelet medication longer than current recommendations may lower heart attack or death risks for patients ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Phase III of CoreValve’s international trial for its patented 18-French Revalving System is now one-third enrolled since ...
The FDA was notified on Dec. 2 that Pfizer will suspend a large, Phase 3 trial evaluating the investigational ...
The FDA will revisit a device tomorrow that it cleared for U.S. sale three years ago — drug-eluting stents will be the ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
The American Heart Association has published a report demonstrating that adolescent boys have a significantly increased ...
The Society for Cardiac Angiography and Interventions (SCAI) has extended the abstract deadline for its 30th Annual ...
One of the major dilemmas faced by clinicians in the Intensive Care Unit (ICU) is the determination of volume status and ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Toronto-based Cedara Software, a Merge Healthcare company and an independent developer of medical software technologies ...
Recent downplay of the media’s attention to DES-related thrombosis during both the TCT and AHA conferences this fall may ...
CV Therapeutics has announced it will file a new drug application to the FDA for its regadenoson agent in mid-2007 ...